Jubilant Pharmova Limited - Asset Resilience Ratio
Jubilant Pharmova Limited (JUBLPHARMA) has an Asset Resilience Ratio of 1.26% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Jubilant Pharmova Limited total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Jubilant Pharmova Limited's Asset Resilience Ratio has changed over time. See net assets of Jubilant Pharmova Limited for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Jubilant Pharmova Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Jubilant Pharmova Limited worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs1.61 Billion | 1.26% |
| Total Liquid Assets | Rs1.61 Billion | 1.26% |
Asset Resilience Insights
- Limited Liquidity: Jubilant Pharmova Limited maintains only 1.26% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jubilant Pharmova Limited Industry Peers by Asset Resilience Ratio
Compare Jubilant Pharmova Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 6.43% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 6.40% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for Jubilant Pharmova Limited (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Jubilant Pharmova Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.00% | Rs5.00 Million ≈ $54.07K |
Rs127.56 Billion ≈ $1.38 Billion |
+0.00pp |
| 2024-03-31 | 0.00% | Rs4.00 Million ≈ $43.26K |
Rs115.48 Billion ≈ $1.25 Billion |
+0.00pp |
| 2023-03-31 | 0.00% | Rs3.84 Million ≈ $41.53K |
Rs111.57 Billion ≈ $1.21 Billion |
-0.05pp |
| 2022-03-31 | 0.05% | Rs53.53 Million ≈ $578.91K |
Rs99.91 Billion ≈ $1.08 Billion |
-2.05pp |
| 2021-03-31 | 2.10% | Rs1.87 Billion ≈ $20.27 Million |
Rs89.18 Billion ≈ $964.46 Million |
+0.61pp |
| 2020-03-31 | 1.50% | Rs1.87 Billion ≈ $20.27 Million |
Rs125.22 Billion ≈ $1.35 Billion |
-1.79pp |
| 2019-03-31 | 3.29% | Rs3.77 Billion ≈ $40.77 Million |
Rs114.69 Billion ≈ $1.24 Billion |
+2.98pp |
| 2018-03-31 | 0.31% | Rs294.56 Million ≈ $3.19 Million |
Rs96.18 Billion ≈ $1.04 Billion |
+0.15pp |
| 2017-03-31 | 0.16% | Rs144.88 Million ≈ $1.57 Million |
Rs90.41 Billion ≈ $977.71 Million |
+0.10pp |
| 2016-03-31 | 0.06% | Rs53.16 Million ≈ $574.91K |
Rs89.47 Billion ≈ $967.59 Million |
-0.02pp |
| 2015-03-31 | 0.08% | Rs66.49 Million ≈ $719.06K |
Rs86.32 Billion ≈ $933.54 Million |
+0.01pp |
| 2014-03-31 | 0.07% | Rs57.63 Million ≈ $623.25K |
Rs88.61 Billion ≈ $958.24 Million |
+0.02pp |
| 2013-03-31 | 0.05% | Rs40.53 Million ≈ $438.32K |
Rs84.32 Billion ≈ $911.89 Million |
-- |
About Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment o… Read more